Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-Moderate Alzheimer's Disease.

Trial Profile

Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Jul 2017 Results of an analysis examining the difference in the magnitude of decline in cognition over 48 weeks between intepirdine in conjunction with donepezil and donepezil alone, reported on a numeric and percentage basis.presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results of responder analysis presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results of medicare cost benefit of intepirdine from this study presented at the Alzheimer's Association International Conference 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top